| Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients V Gopalakrishnan, CN Spencer, L Nezi, A Reuben, MC Andrews, ... Science 359 (6371), 97-103, 2018 | 3936 | 2018 |
| B cells and tertiary lymphoid structures promote immunotherapy response BA Helmink, SM Reddy, J Gao, S Zhang, R Basar, R Thakur, K Yizhak, ... Nature 577 (7791), 549-555, 2020 | 1743 | 2020 |
| Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen LA Johnson, RA Morgan, ME Dudley, L Cassard, JC Yang, MS Hughes, ... Blood, The Journal of the American Society of Hematology 114 (3), 535-546, 2009 | 1738 | 2009 |
| COT drives resistance to RAF inhibition through MAP kinase pathway reactivation CM Johannessen, JS Boehm, SY Kim, SR Thomas, L Wardwell, ... Nature 468 (7326), 968-972, 2010 | 1723 | 2010 |
| The human tumor microbiome is composed of tumor type–specific intracellular bacteria D Nejman, I Livyatan, G Fuks, N Gavert, Y Zwang, LT Geller, ... Science 368 (6494), 973-980, 2020 | 1398 | 2020 |
| Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade SC Wei, JH Levine, AP Cogdill, Y Zhao, NAAS Anang, MC Andrews, ... Cell 170 (6), 1120-1133. e17, 2017 | 1176 | 2017 |
| EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib RB Corcoran, H Ebi, AB Turke, EM Coffee, M Nishino, AP Cogdill, ... Cancer discovery 2 (3), 227-235, 2012 | 1072 | 2012 |
| BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma DT Frederick, A Piris, AP Cogdill, ZA Cooper, C Lezcano, CR Ferrone, ... Clinical cancer research 19 (5), 1225-1231, 2013 | 993 | 2013 |
| Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function A Boni, AP Cogdill, P Dang, D Udayakumar, CNJ Njauw, CM Sloss, ... Cancer research 70 (13), 5213-5219, 2010 | 801 | 2010 |
| Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells JA Fraietta, CL Nobles, MA Sammons, S Lundh, SA Carty, TJ Reich, ... Nature 558 (7709), 307-312, 2018 | 718 | 2018 |
| Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma AD Posey, RD Schwab, AC Boesteanu, C Steentoft, U Mandel, B Engels, ... Immunity 44 (6), 1444-1454, 2016 | 608 | 2016 |
| Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice X Liu, S Jiang, C Fang, S Yang, D Olalere, EC Pequignot, AP Cogdill, N Li, ... Cancer research 75 (17), 3596-3607, 2015 | 558 | 2015 |
| Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia JA Fraietta, KA Beckwith, PR Patel, M Ruella, Z Zheng, DM Barrett, ... Blood, The Journal of the American Society of Hematology 127 (9), 1117-1127, 2016 | 497 | 2016 |
| Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma LA Johnson, J Scholler, T Ohkuri, A Kosaka, PR Patel, SE McGettigan, ... Science translational medicine 7 (275), 275ra22-275ra22, 2015 | 496 | 2015 |
| Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response CN Spencer, JL McQuade, V Gopalakrishnan, JA McCulloch, M Vetizou, ... Science 374 (6575), 1632-1640, 2021 | 445 | 2021 |
| Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies SC Wei, NAAS Anang, R Sharma, MC Andrews, A Reuben, JH Levine, ... Proceedings of the National Academy of Sciences 116 (45), 22699-22709, 2019 | 291 | 2019 |
| Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment KC Lam, RE Araya, A Huang, Q Chen, M Di Modica, RR Rodrigues, ... Cell 184 (21), 5338-5356. e21, 2021 | 278 | 2021 |
| Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade MC Andrews, CPM Duong, V Gopalakrishnan, V Iebba, WS Chen, ... Nature medicine 27 (8), 1432-1441, 2021 | 268 | 2021 |
| Hallmarks of response to immune checkpoint blockade AP Cogdill, MC Andrews, JA Wargo British journal of cancer 117 (1), 1, 2017 | 257 | 2017 |
| Checkpoint blockade reverses anergy in IL-13Rα2 humanized scFv-based CAR T cells to treat murine and canine gliomas Y Yin, AC Boesteanu, ZA Binder, C Xu, RA Reid, JL Rodriguez, DR Cook, ... Molecular Therapy-Oncolytics 11, 20-38, 2018 | 149 | 2018 |
Flaherty KMassachusetts General Hospital, University of Pennsylvania在 mgh.harvard.edu 的电子邮件经过验证
